The negotiation was a simple one. Vaccine makers needed an assured market, and the government, assured supply. Until recently, the lowest bidder for a government tender took it all. Not anymore. The supplier who scores the second place also has value. After a year of dialogue in 2016, there’s finally a consensus. The lowest bidder will supply 60% of the products, while the second lowest will meet the remaining need. Provided, the latter matches the lowest price.

Under the revised rules, on 28 March, the ministry of health closed its first bid to buy 14.5 million doses of rotavirus vaccine for Rs 104.13 crore. After giving two orders of 10 million doses each to Bharat Biotech (Bharat) since its Rotavac launch in March 2015, the ministry is pleased that this time it has an option. Pune-based Serum Institute of India (Serum), the world’s largest vaccine manufacturer by the number of doses produced, is competing with the poster boy of the Indian vaccine industry—Hyderabad-based Bharat. The latter has the first-mover advantage and low price on its side but Serum offers an advanced product.

When Bharat launched Rotavac, two years ago, it was a dollar a dose. Also, the cheapest in comparison with what competitors GlaxoSmithKline (GSK) and Merck were selling in India. It was developed with support from the Indian and the US governments and non-government organisations including the Bill and Melinda Gates Foundation (BMGF). It couldn’t have been better timed because a year later, the Modi government included the rotavirus vaccine in the Universal Immunisation Programme (UIP) in four states—Andhra Pradesh, Haryana, Himachal Pradesh and Odisha. Rotavirus diarrhoea kills between 80,000 to 100,000 children every year.

Meanwhile, slowly and steadily, Serum had been developing a different product, more in tune with the global market. For two dollars a dose, Serum’s Rotasiil offers higher stability, a longer shelf life and reduced wastage with its small doses. No less importantly, it has pushed the government to change its ways of buying from the industry as the vaccine demand for the UIP soars.

More vaccine quantities and the number of children being immunised, up from 65% to 90% by 2020, under the new plan, have been like a booster dose for the Indian vaccine makers. The guaranteed minimum of 40% to the second lowest bidder is a turning point. The current UIP budget of Rs 1000 crore for 2017-18 will see nearly twice the number of suppliers for different vaccines, the credit for which goes to two companies—Bharat and Serum.

Doubling of suppliers

The guaranteed minimum of 40% to the second lowest bidder is a turning point. The current UIP budget of Rs 1000 crore for 2017-18 will see nearly twice the number of suppliers for different vaccines, the credit for which goes to two companies—Bharat and Serum

The hare & the tortoise

The story of Rotavac’s development started in 1985.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.